Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy

Francesco Trotta, Flavia Mayer, Francesco Barone-Adesi, Immacolata Esposito, Ranadhir Punreddy, Roberto Da Cas, Giuseppe Traversa, Francesco Perrone, Nello Martini, Bishal Gyawali, Antonio Addis

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To investigate whether the prices of new anticancer drugs correlated with their relative benefit despite negotiation. DESIGN: Retrospective cross-sectional study correlating new anticancer drugs prices with clinical outcomes. SETTING: We did a retrospective cross-sectional study including all new anticancer drugs approved by the European Medicines Agency (EMA) (2010-2016) and reimbursed in Italy. MAIN OUTCOMES AND MEASURES: Information on clinical outcomes-in terms of median overall survival (OS), median progression-free survival (PFS) and objective response rate (ORR)-was extracted from pivotal trials as reported in the European Public Assessment Reports available on the EMA website. Cost of a full course treatment was estimated on negotiated official and discounted prices. Regression coefficients β, their levels of significance p and the coefficients of determination R2 were estimated adjusting by tumour type. RESULTS: Overall, 30 new anticancer drugs (with 35 indications) were available for analysis. Where data on OS were available, we observed no correlation between the improvement in median OS (in weeks) and negotiated price (R2=0.067, n=16 drugs for 17 indications). When the clinical outcomes were expressed as improvements in the median PFS or ORR, 25 drugs (29 indications) were available for the analysis, and again, there was no correlation with prices (R2=0.004 and 0.006, respectively). CONCLUSIONS AND RELEVANCE: Our results suggest that the prices of anticancer drugs in Italy do not reflect their therapeutic benefit. Drug price negotiations, which is mandatory by law in Italy, do not seem to ensure that prices correlate with clinical benefits provided by the cancer drugs. These results call for further efforts to establish the standard determinants of drug prices available at the time of negotiation. These findings need to be confirmed in other countries where price negotiations are in place. Moreover, further investigations may verify whether outcome data obtained after drug marketing would improve the correlation between prices and therapeutic benefit.

Original languageEnglish
Pages (from-to)e033728
JournalBMJ Open
Volume9
Issue number12
DOIs
Publication statusPublished - Dec 10 2019

Fingerprint

Italy
Cross-Sectional Studies
Pharmaceutical Preparations
Negotiating
Disease-Free Survival
Marketing
Neoplasms
Costs and Cost Analysis
Therapeutics

Keywords

  • antineoplastic agents
  • antineoplastic agents/therapeutic use
  • drug costs
  • treatment outcome

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Trotta, F., Mayer, F., Barone-Adesi, F., Esposito, I., Punreddy, R., Da Cas, R., ... Addis, A. (2019). Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy. BMJ Open, 9(12), e033728. https://doi.org/10.1136/bmjopen-2019-033728

Anticancer drug prices and clinical outcomes : a cross-sectional study in Italy. / Trotta, Francesco; Mayer, Flavia; Barone-Adesi, Francesco; Esposito, Immacolata; Punreddy, Ranadhir; Da Cas, Roberto; Traversa, Giuseppe; Perrone, Francesco; Martini, Nello; Gyawali, Bishal; Addis, Antonio.

In: BMJ Open, Vol. 9, No. 12, 10.12.2019, p. e033728.

Research output: Contribution to journalArticle

Trotta, F, Mayer, F, Barone-Adesi, F, Esposito, I, Punreddy, R, Da Cas, R, Traversa, G, Perrone, F, Martini, N, Gyawali, B & Addis, A 2019, 'Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy', BMJ Open, vol. 9, no. 12, pp. e033728. https://doi.org/10.1136/bmjopen-2019-033728
Trotta F, Mayer F, Barone-Adesi F, Esposito I, Punreddy R, Da Cas R et al. Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy. BMJ Open. 2019 Dec 10;9(12):e033728. https://doi.org/10.1136/bmjopen-2019-033728
Trotta, Francesco ; Mayer, Flavia ; Barone-Adesi, Francesco ; Esposito, Immacolata ; Punreddy, Ranadhir ; Da Cas, Roberto ; Traversa, Giuseppe ; Perrone, Francesco ; Martini, Nello ; Gyawali, Bishal ; Addis, Antonio. / Anticancer drug prices and clinical outcomes : a cross-sectional study in Italy. In: BMJ Open. 2019 ; Vol. 9, No. 12. pp. e033728.
@article{cd77431b37bd46558d5dbd42a7a1e880,
title = "Anticancer drug prices and clinical outcomes: a cross-sectional study in Italy",
abstract = "OBJECTIVE: To investigate whether the prices of new anticancer drugs correlated with their relative benefit despite negotiation. DESIGN: Retrospective cross-sectional study correlating new anticancer drugs prices with clinical outcomes. SETTING: We did a retrospective cross-sectional study including all new anticancer drugs approved by the European Medicines Agency (EMA) (2010-2016) and reimbursed in Italy. MAIN OUTCOMES AND MEASURES: Information on clinical outcomes-in terms of median overall survival (OS), median progression-free survival (PFS) and objective response rate (ORR)-was extracted from pivotal trials as reported in the European Public Assessment Reports available on the EMA website. Cost of a full course treatment was estimated on negotiated official and discounted prices. Regression coefficients β, their levels of significance p and the coefficients of determination R2 were estimated adjusting by tumour type. RESULTS: Overall, 30 new anticancer drugs (with 35 indications) were available for analysis. Where data on OS were available, we observed no correlation between the improvement in median OS (in weeks) and negotiated price (R2=0.067, n=16 drugs for 17 indications). When the clinical outcomes were expressed as improvements in the median PFS or ORR, 25 drugs (29 indications) were available for the analysis, and again, there was no correlation with prices (R2=0.004 and 0.006, respectively). CONCLUSIONS AND RELEVANCE: Our results suggest that the prices of anticancer drugs in Italy do not reflect their therapeutic benefit. Drug price negotiations, which is mandatory by law in Italy, do not seem to ensure that prices correlate with clinical benefits provided by the cancer drugs. These results call for further efforts to establish the standard determinants of drug prices available at the time of negotiation. These findings need to be confirmed in other countries where price negotiations are in place. Moreover, further investigations may verify whether outcome data obtained after drug marketing would improve the correlation between prices and therapeutic benefit.",
keywords = "antineoplastic agents, antineoplastic agents/therapeutic use, drug costs, treatment outcome",
author = "Francesco Trotta and Flavia Mayer and Francesco Barone-Adesi and Immacolata Esposito and Ranadhir Punreddy and {Da Cas}, Roberto and Giuseppe Traversa and Francesco Perrone and Nello Martini and Bishal Gyawali and Antonio Addis",
year = "2019",
month = "12",
day = "10",
doi = "10.1136/bmjopen-2019-033728",
language = "English",
volume = "9",
pages = "e033728",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "12",

}

TY - JOUR

T1 - Anticancer drug prices and clinical outcomes

T2 - a cross-sectional study in Italy

AU - Trotta, Francesco

AU - Mayer, Flavia

AU - Barone-Adesi, Francesco

AU - Esposito, Immacolata

AU - Punreddy, Ranadhir

AU - Da Cas, Roberto

AU - Traversa, Giuseppe

AU - Perrone, Francesco

AU - Martini, Nello

AU - Gyawali, Bishal

AU - Addis, Antonio

PY - 2019/12/10

Y1 - 2019/12/10

N2 - OBJECTIVE: To investigate whether the prices of new anticancer drugs correlated with their relative benefit despite negotiation. DESIGN: Retrospective cross-sectional study correlating new anticancer drugs prices with clinical outcomes. SETTING: We did a retrospective cross-sectional study including all new anticancer drugs approved by the European Medicines Agency (EMA) (2010-2016) and reimbursed in Italy. MAIN OUTCOMES AND MEASURES: Information on clinical outcomes-in terms of median overall survival (OS), median progression-free survival (PFS) and objective response rate (ORR)-was extracted from pivotal trials as reported in the European Public Assessment Reports available on the EMA website. Cost of a full course treatment was estimated on negotiated official and discounted prices. Regression coefficients β, their levels of significance p and the coefficients of determination R2 were estimated adjusting by tumour type. RESULTS: Overall, 30 new anticancer drugs (with 35 indications) were available for analysis. Where data on OS were available, we observed no correlation between the improvement in median OS (in weeks) and negotiated price (R2=0.067, n=16 drugs for 17 indications). When the clinical outcomes were expressed as improvements in the median PFS or ORR, 25 drugs (29 indications) were available for the analysis, and again, there was no correlation with prices (R2=0.004 and 0.006, respectively). CONCLUSIONS AND RELEVANCE: Our results suggest that the prices of anticancer drugs in Italy do not reflect their therapeutic benefit. Drug price negotiations, which is mandatory by law in Italy, do not seem to ensure that prices correlate with clinical benefits provided by the cancer drugs. These results call for further efforts to establish the standard determinants of drug prices available at the time of negotiation. These findings need to be confirmed in other countries where price negotiations are in place. Moreover, further investigations may verify whether outcome data obtained after drug marketing would improve the correlation between prices and therapeutic benefit.

AB - OBJECTIVE: To investigate whether the prices of new anticancer drugs correlated with their relative benefit despite negotiation. DESIGN: Retrospective cross-sectional study correlating new anticancer drugs prices with clinical outcomes. SETTING: We did a retrospective cross-sectional study including all new anticancer drugs approved by the European Medicines Agency (EMA) (2010-2016) and reimbursed in Italy. MAIN OUTCOMES AND MEASURES: Information on clinical outcomes-in terms of median overall survival (OS), median progression-free survival (PFS) and objective response rate (ORR)-was extracted from pivotal trials as reported in the European Public Assessment Reports available on the EMA website. Cost of a full course treatment was estimated on negotiated official and discounted prices. Regression coefficients β, their levels of significance p and the coefficients of determination R2 were estimated adjusting by tumour type. RESULTS: Overall, 30 new anticancer drugs (with 35 indications) were available for analysis. Where data on OS were available, we observed no correlation between the improvement in median OS (in weeks) and negotiated price (R2=0.067, n=16 drugs for 17 indications). When the clinical outcomes were expressed as improvements in the median PFS or ORR, 25 drugs (29 indications) were available for the analysis, and again, there was no correlation with prices (R2=0.004 and 0.006, respectively). CONCLUSIONS AND RELEVANCE: Our results suggest that the prices of anticancer drugs in Italy do not reflect their therapeutic benefit. Drug price negotiations, which is mandatory by law in Italy, do not seem to ensure that prices correlate with clinical benefits provided by the cancer drugs. These results call for further efforts to establish the standard determinants of drug prices available at the time of negotiation. These findings need to be confirmed in other countries where price negotiations are in place. Moreover, further investigations may verify whether outcome data obtained after drug marketing would improve the correlation between prices and therapeutic benefit.

KW - antineoplastic agents

KW - antineoplastic agents/therapeutic use

KW - drug costs

KW - treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=85076417235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076417235&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2019-033728

DO - 10.1136/bmjopen-2019-033728

M3 - Article

C2 - 31826897

AN - SCOPUS:85076417235

VL - 9

SP - e033728

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 12

ER -